Lumakras 120mg Tablet used to treat non-small cell lung cancer (NSCLC) with KRAS G12C mutation. Lung cancer is one of the most common and serious forms of cancer worldwide. It has two main types in which Non-Small Cell Lung Cancer (NSCLC) cause nearly 85% of all cases. NSCLC originates when abnormal cells grow and divide uncontrollably in the lung tissues and start affecting breathing and oxygen supply. Traditional treatment of NSCLC include surgery, chemotherapy, and radiation. However, with advancements in medical science, researchers have identified specific genetic mutations known as KRAS mutation that is responsible for the growth of lung cancer.
What Is the KRAS G12C Mutation?
A protein which helps to regulate the growth of cells is produced by the KRAS gene. The KRAS protein becomes overactive when this gene is mutated, especially in the G12C form, which results in uncontrolled cell division & growth of tumors. KRAS mutations are one of the most common genetic causes of lung cancer, causing 25–30% of NSCLC cases. KRAS mutations were previously believed to be “uncontrollable,” which meant that current treatments were unable to effectively target them. But it has changed because of current breakthroughs in science.
Targeted Therapy and Lumakras 120mg Tablet
Targeted therapy is one of the major treatment approaches in cancer which offers a more advanced treatment strategy with fewer side effects. One such revolutionary targeted therapy is Lumakras 120mg Tablet that is proven beneficial for the KRAS G12C-mutated NSCLC patients. This medicine works by binding and blocking the action of KRAS G12C protein as a result slowing down or stopping the growth of cancer cells. Unlike chemotherapy, this medicine works by targeting only cancerous cells. This medicine offers new hope for patients who have limited treatment options after chemotherapy or immunotherapy.
How Lumakras Tablet Helps in NSCLC
Lumakras Tablet plays a significant role in managing advanced NSCLC with the KRAS G12C mutation. Here’s how it helps:
- Targets the Root Cause
- Improves Treatment Outcomes
- Offers Personalized Therapy
- Better Tolerability
- Improve survival rate and quality of life
- Have fewer and manageable side effects
Conclusion
The discovery and development of Lumakras 120mg Tablet for Non-Small Cell Lung Cancer have transformed the outlook for patients with KRAS-mutated NSCLC. The mutation that was considered untreatable until now can now be targeted effectively. It offers new possibilities for survival and improved quality of life. You can avail this medicine from Gloabans Pharma in a reasonable price range with fast doorstep delivery. It is one of the most trustworthy pharmacies which provides its services on a global level.
FAQ
Q- What is the use of Lumakras 120 mg Tablet?
A- This tablet used to treat non-small cell lung cancer (NSCLC) with KRAS G12C mutation.
Q-What are the common side effects of this tablet?
A- Some patients may experience some common side effects which include diarrhoea, nausea, fatigue, or liver enzyme changes. Always consult your oncologist for guidance.
Q-Where can I buy Lumakras Tablet?
A-You can get this tablet from trusted online pharmacies like Globans Pharma.
